Oddity’s advertising shock has obscured a high-margin, repeat-purchase beauty platform; recovery hinges on lower acquisition costs, while SpoiledChild and METHODIQ offer meaningful growth optionality.
Overview
Oddity Tech is a digital-first beauty and wellness company that builds and scales direct-to-consumer brands using personalization software, consumer data, and proprietary product science. IL MAKIAGE anchors the portfolio, SpoiledChild extends it into wellness, and METHODIQ adds telehealth dermatology, with metabolic-health offerings planned for 2027. Its differentiation includes over 60 million registered users, reported shade-matching accuracy above 90%, eight commercialized ODDITY Labs molecules, and repeat purchases representing approximately 70% of FY2025 revenue. The company’s record growth and margins were disrupted by a late-2025 advertising-platform algorithm change: customer acquisition costs rose about 50%, contributing to a 25% Q2 2026 revenue decline and an expected 18.5% FY2026 decline to roughly $660 million. Q3 improved materially, with $145 million revenue, down 2%, and $22 million adjusted EBITDA; management raised FY2026 EBITDA guidance to $32–$34 million. **The investment case is a recovery in ad efficiency and operating leverage**, with SpoiledChild approaching $350 million in 2026 sales and METHODIQ expanding the addressable market. At $20.18, the stock trades at 1.32x TTM EV/sales and 17.7x consensus FY2027 EPS, against a report-derived probability-weighted five-year target of $70.29. Near-term catalysts are Meta remediation, 2027 guidance, and METHODIQ’s expansion; execution and regulatory risks remain substantial.